Jaguar health to present october 3 at ld micro's main event investor conference, and on october 5 at the global capital network investor conference

Top line results expected late october 2023 for company's phase 3 ontarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the us, eu, and middle east/north africa regions, with results expected before the end of 2023 and in 2024 san francisco, ca / accesswire / september 28, 2023 / jaguar health, inc. (nasdaq:jagx) today announced that company management will present at the ld micro main event investor conference on october 3, 2023, and at the global capital network investor conference on october 5, 2023. participation instructions for jaguar presentation at ld micro main event when: tuesday, october 3, 2023 from 12:00-12:25 pm pacific daylight time in track 3 where: luxe sunset boulevard hotel, 11461 sunset blvd, los angeles, ca 90049 registration link for conference: click here participation instructions for jaguar presentation at global capital network investor conference when: thursday, october 5, 2023 during the medtech segment of the conference where: newport beach hyatt, 1107 jamboree, newport beach, ca 92660 registration link for conference: click here as recently announced by napo pharmaceuticals (napo), a jaguar family company, the last patient has completed their final visit for the stage 1 primary endpoint treatment period of napo's pivotal phase 3 ontarget trial of crofelemer for preventive treatment of diarrhea in adult cancer patients with solid tumors receiving targeted therapy with or without standard chemotherapy.
JAGX Ratings Summary
JAGX Quant Ranking